knowledge -WSS

knowledge

author：fashion 2025-09-06 02:06:37 - browse：4497

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： 2 officers injured in shooting in Orlando, police say

WSS

Medicare Advantage proposed rates disappoint insurers

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

A controversial new treatment promises to make little people taller

Pharma showers House GOP doctor with campaign cash

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Wikipedia

knowledge

Wikipedia

Supreme Court strikes down use of affirmative action

Doctors' information doesn't help them choose wisely when sick

Affirmative action in medical school literally saved lives

'Null' research findings aren't empty of meaning. Let's publish them

BioMarin wins approval for gene therapy to treat hemophilia A

Biden report: The neurospychology of memory and aging

Drug repurposing or repositioning? The language matters

Biogen Alzheimer’s drug launch off to slow start

As demand for Covid shots wanes, Moderna seeks its next success

FDA approves Sage Therapeutics’ rapid

hotspot

Industry veterans launch new biotech VC with $310M

How I helped Pfizer think through the ethics of Viagra

Gilead might be held responsible for not developing a drug

How I helped Pfizer think through the ethics of Viagra

KalVista pill reduced swelling 'attacks' caused by genetic disease

KalVista pill reduced swelling 'attacks' caused by genetic disease

explore

Wikipedia

explore

hotspot